PCOS Renamed PMOS:
The Long-Overdue Reframe in Women's Reproductive Health
In 2025, The Lancet announced the formal reclassification of Polycystic Ovary Syndrome (PCOS) as Polyendocrine Metabolic Ovarian Syndrome (PMOS) following a global consensus involving 56 academic, clinical, and patient organizations. This updated terminology more accurately reflects the condition's complex, multisystem nature and represents an important step toward improving diagnosis, treatment, and patient care.
Why the Name Change Matters
For decades, the term Polycystic Ovary Syndrome placed emphasis on ovarian cysts --even though many women with the condition never develop them. This narrow focus overlooked the significant endocrine and metabolic dysfunction underlying the disorder, contributing to delayed diagnosis, fragmented care, and misunderstanding of symptoms.
PMOS affects an estimated 10 -13% of reproductive-age women worldwide, yet many remain undiagnosed because their symptoms extend well beyond reproductive health. In addition to menstrual irregularities and infertility, women may experience insulin resistance, type 2 diabetes, obesity, cardiovascular disease, sleep disturbances, mood disorders, acne, and androgen-related symptoms such as hair loss or hirsutism.
Recognizing PMOS as a whole-body condition encourages clinicians to look beyond the ovaries and address the broader hormonal and metabolic picture.
Understanding PMOS
The new name reflects the three major systems involved:
- Polyendocrine: PMOS affects multiple hormonal pathways, including reproductive hormones, insulin, and stress hormones, helping explain its association with anxiety, depression, and other systemic symptoms.
- Metabolic: Insulin resistance is a hallmark feature, increasing the risk of weight gain, dyslipidemia, cardiovascular disease, and impaired glucose regulation.
- Ovarian: Ovarian dysfunction remains central, but the emphasis shifts away from ovarian cysts toward irregular ovulation, hormonal imbalance, and fertility challenges.
This broader perspective recognizes ovarian dysfunction as one component of a much larger clinical picture.
A More Comprehensive Evaluation
Women presenting with weight management concerns, fatigue, acne, mood changes, sleep disturbances, or irregular menstrual cycles may benefit from a more comprehensive evaluation. In addition to reproductive hormone testing, clinicians may consider assessing fasting glucose and insulin, hemoglobin A1C, lipid status, androgen levels, estrogen, progesterone, luteinizing hormone (LH), and follicle-stimulating hormone (FSH) to better understand endocrine, metabolic, and hypothalamic-pituitary-ovarian (HPO) axis function.
A Whole-Body Approach to Management
Reframing PCOS as PMOS supports a more integrative treatment strategy that addresses endocrine regulation, metabolic health, and nervous system balance.
Nutrition plays a foundational role. A low-glycemic Mediterranean-style dietary pattern has been shown to support insulin sensitivity, reduce inflammation, and provide healthy fats necessary for hormone production. In some individuals, short-term ketogenic interventions may further improve metabolic health when appropriately supervised.
Targeted nutrients and botanicals may also provide meaningful support. Research has demonstrated benefits from ingredients such as myo-inositol, omega-3 fatty acids, berberine, white peony, licorice, gymnema, saw palmetto, and magnesium, each supporting various aspects of insulin regulation, hormone balance, inflammation, or androgen metabolism. Additionally, consuming cruciferous vegetables may help support healthy estrogen metabolism and liver detoxification, further contributing to hormonal balance.
Regular physical activity remains one of the most effective lifestyle interventions. Both aerobic exercise and resistance training improve insulin sensitivity, metabolic function, body composition, mood, and endocrine health. Current recommendations encourage at least 150 minutes of moderate-intensity exercise each week, along with two sessions of strength training.
Clinical Takeaway
The transition from PCOS to PMOS represents far more than a change in terminology. It acknowledges what patients and many clinicians have long recognized - that this condition extends well beyond the ovaries and requires a comprehensive, whole-body approach to care.
By recognizing the interconnected roles of endocrine, metabolic, and reproductive health, PMOS provides a more accurate framework for diagnosis, patient education, and personalized treatment. This updated perspective has the potential to improve earlier recognition, reduce stigma, and ultimately enhance quality of life for the millions of women living with this complex condition.